Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma.

NCT04230759 is registered in ClinicalTrials.gov with Goethe University as lead sponsor.

NCT NCT04230759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04230759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma.
Lead sponsor
Goethe University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 7, 2020
Completion date
March 31, 2027
Enrollment
180 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer, anal cancer stage ii, anal cancer stage iii, anal carcinoma